A new once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease has been launched.
The product, manufactured by GlaxoSmithKline, combines the drug treatment Incruse (umeclidinium) and the Ellipta device.
Umeclidinium 55 mcg is a once-daily long-acting muscarinic antagonist (LAMA), which can relax airway muscles and improve airflow in and out of the lungs.
NICE guidelines recommend offering a LAMA in addition to an inhaled corticosteroid/long-acting beta agonist (ICS/LABA) as “triple therapy” to patients with COPD who remain breathless or have exacerbations despite taking ICS/LABA alone.
GlaxSmithKline said umeclidinium gave clinicians a new LAMA option, which could be of particular help to support the 65% of LAMA patients who used it alongside a combination ICS/LABA treatment.
The launch of Incruse follows marketing authorisation in April 2014.